img

Global Pelvic Inflammatory Disease (PID) Treatment Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Pelvic Inflammatory Disease (PID) Treatment Market Research Report 2024

Several types of antibiotics can cure PID. Antibiotic treatment does not, however, reverse any scarring caused by the infection. For this reason, it is critical that a woman receive care immediately if she has pelvic pain or other symptoms of PID. Prompt antibiotic treatment can prevent severe damage to the reproductive organs. The longer a woman delays treatment for PID, the more likely she is to become infertile or to have a future ectopic pregnancy because of damage to the fallopian tubes.
According to MRAResearch’s new survey, global Pelvic Inflammatory Disease (PID) Treatment market is projected to reach US$ 1102 million in 2033, increasing from US$ 753 million in 2022, with the CAGR of 5.7% during the period of 2023 to 2033.
The global pelvic inflammatory disease (PID) treatment market pertains to the market for therapies and medications used in the management and treatment of pelvic inflammatory disease. PID is an infection of the female reproductive organs, primarily the uterus, fallopian tubes, and ovaries, usually caused by sexually transmitted bacteria.
Here are some key factors driving the growth of the global PID treatment market
High prevalence of pelvic inflammatory diseasePelvic inflammatory disease is a common gynecological infection, particularly among sexually active women. The incidence of PID continues to rise globally, driving the demand for effective treatment options. Factors such as unsafe sexual practices, multiple sexual partners, and lack of awareness contribute to the high prevalence of PID.
Increasing awareness and early diagnosisThere is a growing emphasis on early diagnosis and prompt treatment of pelvic inflammatory disease to prevent complications and long-term reproductive health issues. Healthcare campaigns, educational initiatives, and improved access to healthcare services contribute to increased awareness and early detection of PID, positively impacting the treatment market.
Rising rates of sexually transmitted infectionsPelvic inflammatory disease is often a complication of sexually transmitted infections (STIs) such as chlamydia and gonorrhea. The global increase in the incidence of STIs, particularly among young adults, fuels the demand for PID treatment. Combatting the spread of STIs remains a priority for public health organizations, stimulating the market growth.
Technological advancementsAdvances in medical technology and diagnostic techniques facilitate early and accurate diagnosis of PID. Modern imaging modalities, such as ultrasound and laparoscopy, aid in identifying the extent of infection and guide treatment decisions. Additionally, the development of novel therapeutics and treatment approaches contributes to market growth.
Development of effective treatment optionsThe pharmaceutical industry continues to invest in research and development activities focused on developing new and effective treatment options for PID. Antibiotics are the primary mode of treatment for PID, and efforts to improve their efficacy, reduce antibiotic resistance, and explore alternative therapies drive market growth.
Government initiatives and healthcare policiesGovernments and healthcare organizations worldwide are implementing initiatives to address the burden of sexually transmitted infections and related complications, including PID. These initiatives include awareness campaigns, routine STI screening, accessible healthcare services, and subsidized or free treatment options. Supportive healthcare policies create a favorable environment for market growth.
In summary, the global pelvic inflammatory disease (PID) treatment market is driven by factors such as the high prevalence of PID, increasing awareness and early diagnosis, rising rates of sexually transmitted infections, technological advancements, development of effective treatment options, and government initiatives. As efforts to diagnose and treat PID improve, and with the focus on reducing complications and improving reproductive health outcomes, the global PID treatment market is expected to grow in the coming years.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Pelvic Inflammatory Disease (PID) Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Roche Holding AG
Pfizer Inc.
Lupin
Cambrex Corporation
Cipla Inc.
Bayer AG
Daiichi Sankyo
Merck & Co., Inc
Allergan plc
Actavis, Inc
Novartis A
Segment by Type
Quinolones
Tetracycline
Beta-lactam
Nitroimidazoles
Others

Segment by Application


Subacute Pelvic Inflammatory Disease
Chronic Pelvic Inflammatory Disease
Sexually Transmitted Pelvic Inflammatory Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pelvic Inflammatory Disease (PID) Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pelvic Inflammatory Disease (PID) Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Quinolones
1.2.3 Tetracycline
1.2.4 Beta-lactam
1.2.5 Nitroimidazoles
1.2.6 Others
1.3 Market by Application
1.3.1 Global Pelvic Inflammatory Disease (PID) Treatment Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Subacute Pelvic Inflammatory Disease
1.3.3 Chronic Pelvic Inflammatory Disease
1.3.4 Sexually Transmitted Pelvic Inflammatory Disease
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pelvic Inflammatory Disease (PID) Treatment Market Perspective (2018-2033)
2.2 Pelvic Inflammatory Disease (PID) Treatment Growth Trends by Region
2.2.1 Global Pelvic Inflammatory Disease (PID) Treatment Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Pelvic Inflammatory Disease (PID) Treatment Historic Market Size by Region (2018-2023)
2.2.3 Pelvic Inflammatory Disease (PID) Treatment Forecasted Market Size by Region (2024-2033)
2.3 Pelvic Inflammatory Disease (PID) Treatment Market Dynamics
2.3.1 Pelvic Inflammatory Disease (PID) Treatment Industry Trends
2.3.2 Pelvic Inflammatory Disease (PID) Treatment Market Drivers
2.3.3 Pelvic Inflammatory Disease (PID) Treatment Market Challenges
2.3.4 Pelvic Inflammatory Disease (PID) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pelvic Inflammatory Disease (PID) Treatment Players by Revenue
3.1.1 Global Top Pelvic Inflammatory Disease (PID) Treatment Players by Revenue (2018-2023)
3.1.2 Global Pelvic Inflammatory Disease (PID) Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Pelvic Inflammatory Disease (PID) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pelvic Inflammatory Disease (PID) Treatment Revenue
3.4 Global Pelvic Inflammatory Disease (PID) Treatment Market Concentration Ratio
3.4.1 Global Pelvic Inflammatory Disease (PID) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pelvic Inflammatory Disease (PID) Treatment Revenue in 2022
3.5 Pelvic Inflammatory Disease (PID) Treatment Key Players Head office and Area Served
3.6 Key Players Pelvic Inflammatory Disease (PID) Treatment Product Solution and Service
3.7 Date of Enter into Pelvic Inflammatory Disease (PID) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pelvic Inflammatory Disease (PID) Treatment Breakdown Data by Type
4.1 Global Pelvic Inflammatory Disease (PID) Treatment Historic Market Size by Type (2018-2023)
4.2 Global Pelvic Inflammatory Disease (PID) Treatment Forecasted Market Size by Type (2024-2033)
5 Pelvic Inflammatory Disease (PID) Treatment Breakdown Data by Application
5.1 Global Pelvic Inflammatory Disease (PID) Treatment Historic Market Size by Application (2018-2023)
5.2 Global Pelvic Inflammatory Disease (PID) Treatment Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Pelvic Inflammatory Disease (PID) Treatment Market Size (2018-2033)
6.2 North America Pelvic Inflammatory Disease (PID) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2018-2023)
6.4 North America Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pelvic Inflammatory Disease (PID) Treatment Market Size (2018-2033)
7.2 Europe Pelvic Inflammatory Disease (PID) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2018-2023)
7.4 Europe Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pelvic Inflammatory Disease (PID) Treatment Market Size (2018-2033)
8.2 Asia-Pacific Pelvic Inflammatory Disease (PID) Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Pelvic Inflammatory Disease (PID) Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Pelvic Inflammatory Disease (PID) Treatment Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pelvic Inflammatory Disease (PID) Treatment Market Size (2018-2033)
9.2 Latin America Pelvic Inflammatory Disease (PID) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2018-2023)
9.4 Latin America Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pelvic Inflammatory Disease (PID) Treatment Market Size (2018-2033)
10.2 Middle East & Africa Pelvic Inflammatory Disease (PID) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche Holding AG
11.1.1 Roche Holding AG Company Detail
11.1.2 Roche Holding AG Business Overview
11.1.3 Roche Holding AG Pelvic Inflammatory Disease (PID) Treatment Introduction
11.1.4 Roche Holding AG Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
11.1.5 Roche Holding AG Recent Development
11.2 Pfizer Inc.
11.2.1 Pfizer Inc. Company Detail
11.2.2 Pfizer Inc. Business Overview
11.2.3 Pfizer Inc. Pelvic Inflammatory Disease (PID) Treatment Introduction
11.2.4 Pfizer Inc. Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
11.2.5 Pfizer Inc. Recent Development
11.3 Lupin
11.3.1 Lupin Company Detail
11.3.2 Lupin Business Overview
11.3.3 Lupin Pelvic Inflammatory Disease (PID) Treatment Introduction
11.3.4 Lupin Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
11.3.5 Lupin Recent Development
11.4 Cambrex Corporation
11.4.1 Cambrex Corporation Company Detail
11.4.2 Cambrex Corporation Business Overview
11.4.3 Cambrex Corporation Pelvic Inflammatory Disease (PID) Treatment Introduction
11.4.4 Cambrex Corporation Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
11.4.5 Cambrex Corporation Recent Development
11.5 Cipla Inc.
11.5.1 Cipla Inc. Company Detail
11.5.2 Cipla Inc. Business Overview
11.5.3 Cipla Inc. Pelvic Inflammatory Disease (PID) Treatment Introduction
11.5.4 Cipla Inc. Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
11.5.5 Cipla Inc. Recent Development
11.6 Bayer AG
11.6.1 Bayer AG Company Detail
11.6.2 Bayer AG Business Overview
11.6.3 Bayer AG Pelvic Inflammatory Disease (PID) Treatment Introduction
11.6.4 Bayer AG Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
11.6.5 Bayer AG Recent Development
11.7 Daiichi Sankyo
11.7.1 Daiichi Sankyo Company Detail
11.7.2 Daiichi Sankyo Business Overview
11.7.3 Daiichi Sankyo Pelvic Inflammatory Disease (PID) Treatment Introduction
11.7.4 Daiichi Sankyo Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
11.7.5 Daiichi Sankyo Recent Development
11.8 Merck & Co., Inc
11.8.1 Merck & Co., Inc Company Detail
11.8.2 Merck & Co., Inc Business Overview
11.8.3 Merck & Co., Inc Pelvic Inflammatory Disease (PID) Treatment Introduction
11.8.4 Merck & Co., Inc Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
11.8.5 Merck & Co., Inc Recent Development
11.9 Allergan plc
11.9.1 Allergan plc Company Detail
11.9.2 Allergan plc Business Overview
11.9.3 Allergan plc Pelvic Inflammatory Disease (PID) Treatment Introduction
11.9.4 Allergan plc Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
11.9.5 Allergan plc Recent Development
11.10 Actavis, Inc
11.10.1 Actavis, Inc Company Detail
11.10.2 Actavis, Inc Business Overview
11.10.3 Actavis, Inc Pelvic Inflammatory Disease (PID) Treatment Introduction
11.10.4 Actavis, Inc Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
11.10.5 Actavis, Inc Recent Development
11.11 Novartis A
11.11.1 Novartis A Company Detail
11.11.2 Novartis A Business Overview
11.11.3 Novartis A Pelvic Inflammatory Disease (PID) Treatment Introduction
11.11.4 Novartis A Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
11.11.5 Novartis A Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Pelvic Inflammatory Disease (PID) Treatment Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Quinolones
Table 3. Key Players of Tetracycline
Table 4. Key Players of Beta-lactam
Table 5. Key Players of Nitroimidazoles
Table 6. Key Players of Others
Table 7. Global Pelvic Inflammatory Disease (PID) Treatment Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Pelvic Inflammatory Disease (PID) Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 9. Global Pelvic Inflammatory Disease (PID) Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Pelvic Inflammatory Disease (PID) Treatment Market Share by Region (2018-2023)
Table 11. Global Pelvic Inflammatory Disease (PID) Treatment Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 12. Global Pelvic Inflammatory Disease (PID) Treatment Market Share by Region (2024-2033)
Table 13. Pelvic Inflammatory Disease (PID) Treatment Market Trends
Table 14. Pelvic Inflammatory Disease (PID) Treatment Market Drivers
Table 15. Pelvic Inflammatory Disease (PID) Treatment Market Challenges
Table 16. Pelvic Inflammatory Disease (PID) Treatment Market Restraints
Table 17. Global Pelvic Inflammatory Disease (PID) Treatment Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Pelvic Inflammatory Disease (PID) Treatment Market Share by Players (2018-2023)
Table 19. Global Top Pelvic Inflammatory Disease (PID) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pelvic Inflammatory Disease (PID) Treatment as of 2022)
Table 20. Ranking of Global Top Pelvic Inflammatory Disease (PID) Treatment Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Pelvic Inflammatory Disease (PID) Treatment Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Pelvic Inflammatory Disease (PID) Treatment Product Solution and Service
Table 24. Date of Enter into Pelvic Inflammatory Disease (PID) Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Pelvic Inflammatory Disease (PID) Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Pelvic Inflammatory Disease (PID) Treatment Revenue Market Share by Type (2018-2023)
Table 28. Global Pelvic Inflammatory Disease (PID) Treatment Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 29. Global Pelvic Inflammatory Disease (PID) Treatment Revenue Market Share by Type (2024-2033)
Table 30. Global Pelvic Inflammatory Disease (PID) Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Pelvic Inflammatory Disease (PID) Treatment Revenue Market Share by Application (2018-2023)
Table 32. Global Pelvic Inflammatory Disease (PID) Treatment Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 33. Global Pelvic Inflammatory Disease (PID) Treatment Revenue Market Share by Application (2024-2033)
Table 34. North America Pelvic Inflammatory Disease (PID) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. North America Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 37. Europe Pelvic Inflammatory Disease (PID) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 38. Europe Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 40. Asia-Pacific Pelvic Inflammatory Disease (PID) Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 41. Asia-Pacific Pelvic Inflammatory Disease (PID) Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Pelvic Inflammatory Disease (PID) Treatment Market Size by Region (2024-2033) & (US$ Million)
Table 43. Latin America Pelvic Inflammatory Disease (PID) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Latin America Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 46. Middle East & Africa Pelvic Inflammatory Disease (PID) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 47. Middle East & Africa Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Pelvic Inflammatory Disease (PID) Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 49. Roche Holding AG Company Detail
Table 50. Roche Holding AG Business Overview
Table 51. Roche Holding AG Pelvic Inflammatory Disease (PID) Treatment Product
Table 52. Roche Holding AG Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023) & (US$ Million)
Table 53. Roche Holding AG Recent Development
Table 54. Pfizer Inc. Company Detail
Table 55. Pfizer Inc. Business Overview
Table 56. Pfizer Inc. Pelvic Inflammatory Disease (PID) Treatment Product
Table 57. Pfizer Inc. Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023) & (US$ Million)
Table 58. Pfizer Inc. Recent Development
Table 59. Lupin Company Detail
Table 60. Lupin Business Overview
Table 61. Lupin Pelvic Inflammatory Disease (PID) Treatment Product
Table 62. Lupin Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023) & (US$ Million)
Table 63. Lupin Recent Development
Table 64. Cambrex Corporation Company Detail
Table 65. Cambrex Corporation Business Overview
Table 66. Cambrex Corporation Pelvic Inflammatory Disease (PID) Treatment Product
Table 67. Cambrex Corporation Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023) & (US$ Million)
Table 68. Cambrex Corporation Recent Development
Table 69. Cipla Inc. Company Detail
Table 70. Cipla Inc. Business Overview
Table 71. Cipla Inc. Pelvic Inflammatory Disease (PID) Treatment Product
Table 72. Cipla Inc. Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023) & (US$ Million)
Table 73. Cipla Inc. Recent Development
Table 74. Bayer AG Company Detail
Table 75. Bayer AG Business Overview
Table 76. Bayer AG Pelvic Inflammatory Disease (PID) Treatment Product
Table 77. Bayer AG Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023) & (US$ Million)
Table 78. Bayer AG Recent Development
Table 79. Daiichi Sankyo Company Detail
Table 80. Daiichi Sankyo Business Overview
Table 81. Daiichi Sankyo Pelvic Inflammatory Disease (PID) Treatment Product
Table 82. Daiichi Sankyo Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023) & (US$ Million)
Table 83. Daiichi Sankyo Recent Development
Table 84. Merck & Co., Inc Company Detail
Table 85. Merck & Co., Inc Business Overview
Table 86. Merck & Co., Inc Pelvic Inflammatory Disease (PID) Treatment Product
Table 87. Merck & Co., Inc Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023) & (US$ Million)
Table 88. Merck & Co., Inc Recent Development
Table 89. Allergan plc Company Detail
Table 90. Allergan plc Business Overview
Table 91. Allergan plc Pelvic Inflammatory Disease (PID) Treatment Product
Table 92. Allergan plc Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023) & (US$ Million)
Table 93. Allergan plc Recent Development
Table 94. Actavis, Inc Company Detail
Table 95. Actavis, Inc Business Overview
Table 96. Actavis, Inc Pelvic Inflammatory Disease (PID) Treatment Product
Table 97. Actavis, Inc Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023) & (US$ Million)
Table 98. Actavis, Inc Recent Development
Table 99. Novartis A Company Detail
Table 100. Novartis A Business Overview
Table 101. Novartis A Pelvic Inflammatory Disease (PID) Treatment Product
Table 102. Novartis A Revenue in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023) & (US$ Million)
Table 103. Novartis A Recent Development
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Pelvic Inflammatory Disease (PID) Treatment Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Pelvic Inflammatory Disease (PID) Treatment Market Share by Type: 2022 VS 2033
Figure 3. Quinolones Features
Figure 4. Tetracycline Features
Figure 5. Beta-lactam Features
Figure 6. Nitroimidazoles Features
Figure 7. Others Features
Figure 8. Global Pelvic Inflammatory Disease (PID) Treatment Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 9. Global Pelvic Inflammatory Disease (PID) Treatment Market Share by Application: 2022 VS 2033
Figure 10. Subacute Pelvic Inflammatory Disease Case Studies
Figure 11. Chronic Pelvic Inflammatory Disease Case Studies
Figure 12. Sexually Transmitted Pelvic Inflammatory Disease Case Studies
Figure 13. Others Case Studies
Figure 14. Pelvic Inflammatory Disease (PID) Treatment Report Years Considered
Figure 15. Global Pelvic Inflammatory Disease (PID) Treatment Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 16. Global Pelvic Inflammatory Disease (PID) Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 17. Global Pelvic Inflammatory Disease (PID) Treatment Market Share by Region: 2022 VS 2033
Figure 18. Global Pelvic Inflammatory Disease (PID) Treatment Market Share by Players in 2022
Figure 19. Global Top Pelvic Inflammatory Disease (PID) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pelvic Inflammatory Disease (PID) Treatment as of 2022)
Figure 20. The Top 10 and 5 Players Market Share by Pelvic Inflammatory Disease (PID) Treatment Revenue in 2022
Figure 21. North America Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. North America Pelvic Inflammatory Disease (PID) Treatment Market Share by Country (2018-2033)
Figure 23. United States Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Canada Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Europe Pelvic Inflammatory Disease (PID) Treatment Market Share by Country (2018-2033)
Figure 27. Germany Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. France Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. U.K. Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Italy Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Russia Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Nordic Countries Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Asia-Pacific Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Asia-Pacific Pelvic Inflammatory Disease (PID) Treatment Market Share by Region (2018-2033)
Figure 35. China Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Japan Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. South Korea Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Southeast Asia Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. India Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Australia Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Latin America Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Latin America Pelvic Inflammatory Disease (PID) Treatment Market Share by Country (2018-2033)
Figure 43. Mexico Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Brazil Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Middle East & Africa Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Middle East & Africa Pelvic Inflammatory Disease (PID) Treatment Market Share by Country (2018-2033)
Figure 47. Turkey Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Saudi Arabia Pelvic Inflammatory Disease (PID) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 49. Roche Holding AG Revenue Growth Rate in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
Figure 50. Pfizer Inc. Revenue Growth Rate in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
Figure 51. Lupin Revenue Growth Rate in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
Figure 52. Cambrex Corporation Revenue Growth Rate in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
Figure 53. Cipla Inc. Revenue Growth Rate in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
Figure 54. Bayer AG Revenue Growth Rate in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
Figure 55. Daiichi Sankyo Revenue Growth Rate in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
Figure 56. Merck & Co., Inc Revenue Growth Rate in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
Figure 57. Allergan plc Revenue Growth Rate in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
Figure 58. Actavis, Inc Revenue Growth Rate in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
Figure 59. Novartis A Revenue Growth Rate in Pelvic Inflammatory Disease (PID) Treatment Business (2018-2023)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries